Granules Pharmaceuticals concludes USFDA audit in Preapproval Inspection of subsidiary's two products; Stock spurts 2%

31 Jan 2022 , 09:30 AM

Granules India Limited announced on Monday that wholly-owned subsidiary Granules Pharmaceuticals, Inc. (GPI), located in Chantilly, Virginia, USA had undergone a Preapproval Inspection (PAI) by the US Food and Drug Administration (USFDA) from January 24-28, 2022.

The audit is a PAI for two of its product applications filed from this facility. The USFDA issued three minor observations during the audit conducted at the facility.

“We are glad to have completed yet another audit with minor observations that we will respond to within the stipulated time period,” Priyanka Chigurupati, Executive Director, GPI, said.

At around 9.30 am, Granules India Ltd was trading at Rs306.45 per piece up by Rs5.95 or 1.98% from its previous closing of Rs300.50 per piece on the BSE.